Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Amortization of Deferred Charges (2016 - 2023)

Historic Amortization of Deferred Charges for Protalix BioTherapeutics (PLX) over the last 11 years, with Q4 2023 value amounting to $59000.0.

  • Protalix BioTherapeutics' Amortization of Deferred Charges fell 2236.84% to $59000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $267000.0, marking a year-over-year decrease of 1100.0%. This contributed to the annual value of $267000.0 for FY2023, which is 1100.0% down from last year.
  • According to the latest figures from Q4 2023, Protalix BioTherapeutics' Amortization of Deferred Charges is $59000.0, which was down 2236.84% from $60000.0 recorded in Q3 2023.
  • Over the past 5 years, Protalix BioTherapeutics' Amortization of Deferred Charges peaked at $983000.0 during Q2 2021, and registered a low of $59000.0 during Q4 2023.
  • Its 5-year average for Amortization of Deferred Charges is $485050.0, with a median of $672500.0 in 2019.
  • In the last 5 years, Protalix BioTherapeutics' Amortization of Deferred Charges soared by 1647.73% in 2020 and then tumbled by 9277.72% in 2022.
  • Protalix BioTherapeutics' Amortization of Deferred Charges (Quarter) stood at $794000.0 in 2019, then grew by 16.12% to $922000.0 in 2020, then plummeted by 88.72% to $104000.0 in 2021, then fell by 26.92% to $76000.0 in 2022, then decreased by 22.37% to $59000.0 in 2023.
  • Its Amortization of Deferred Charges was $59000.0 in Q4 2023, compared to $60000.0 in Q3 2023 and $68000.0 in Q2 2023.